Comparative Pharmacology
Head-to-head clinical analysis: LUPRON DEPOT versus VANTAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUPRON DEPOT versus VANTAS.
LUPRON DEPOT vs VANTAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) agonist. Continuous administration suppresses pituitary gonadotropin (LH and FSH) secretion, leading to reduced gonadal steroidogenesis (testosterone and estrogen). Initial transient stimulation may occur.
Gonadotropin-releasing hormone (GnRH) agonist; continuous stimulation suppresses pituitary gonadotropin secretion, resulting in decreased testosterone production.
3.75 mg IM monthly for endometriosis; 3.75 mg IM monthly or 11.25 mg IM every 3 months for central precocious puberty; 7.5 mg IM monthly for prostate cancer.
10 mg subcutaneously every 24 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours after single subcutaneous dose; with depot formulations, the apparent half-life is prolonged due to slow release (e.g., 1-month depot: 30 days).
Terminal elimination half-life approximately 4 weeks (28 days) due to continuous release from the implant; after implant removal, plasma concentrations decline with a half-life of about 3-4 days.
Primarily renal (90% as unchanged drug and metabolites); biliary/fecal elimination is minimal.
Renal: negligible. Fecal: ~100% (unchanged drug). Histrelin is not metabolized and is excreted unchanged in feces via biliary elimination.
Category C
Category C
GnRH Agonist
GnRH Agonist